Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway regulates phase 2 detoxification genes, including a variety of antioxidative enzymes. We tested neuroprotective effects of the synthetic triterpenoid CDDO-MA, a potent activator of the Nrf2/ARE signaling. CDDO-MA treatment of neuroblastoma SH-SY5Y cells resulted in Nrf2 upregulation and translocation from cytosol to nucleus and subsequent activation of ARE pathway genes. CDDO-MA blocked t-butylhydroperoxide-induced production of reactive oxygen species (ROS) by activation of ARE genes only in wild type, but not Nrf2 knockout mouse embryonic fibroblasts. Oral administration of CDDO-MA resulted in significant protection against MPTP-induced nigrostriatal dopaminergic neurodegeneration, pathological alpha-synuclein accumulation and oxidative damage in mice. Additionally, CDDO-MA treatment in rats produced significant rescue against striatal lesions caused by the neurotoxin 3-NP, and associated increases in the oxidative damage markers malondialdehyde, F(2)-Isoprostanes, 8-hydroxy-2-deoxyguanosine, 3-nitrotyrosine, and impaired glutathione homeostasis. Our results indicate that the CDDO-MA renders its neuroprotective effects through its potent activation of the Nrf2/ARE pathway, and suggest that triterpenoids may be beneficial for the treatment of neurodegenerative diseases like Parkinson's disease and Huntington's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“pathogenesis of neurodegenerative diseases such as Parkinson’s disease (PD) and Huntington’s disease (HD) [1,2].”
BackgroundSelf-citationWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Klivenyi, P., Andreassen, O. A., Ferrante, R. J., Dedeoglu, A., Mueller, G., Lancelot, E., Bogdanov, M., Andersen, J. K., Jiang, D., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00001.2000 · Cited by 1,111
Self-citationLiberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 1×
“Both iNOS- and COX2-deficient mice are resistant to dopaminergic neurotoxicity in a mouse model of PD [17,18].”
BackgroundThomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Self-citationMartin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684 · cited 1×
“Interestingly, mice lacking a-synuclein are resistant to mitochondrial toxins [31,42] whereas human A53T asynuclein-overexpressing mice are known to develop neuronal mitochondrial degeneration and cell death through induction of oxidative stress [43,44].”
BackgroundTriterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637 · cited 3×
“This reaction activates the phase 2 responses, an intrinsic mechanism used by cells to deactivate electrophiles or oxidative stress [12].”
BackgroundInfluentialSelf-citationChen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Nrf2, a multi‐organ protector?
Lee, J., Li, J., Johnson, D. A., Stein, T. D., Kraft, A. D., Calkins, M. J., Jakel, R. J., & Johnson, J. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-2591hyp · Cited by 532
Cited by
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
“…neurotoxicity of activated microglial cultures on dopaminergic neuron-like cells (Tran et al., 2008) and its brainpermeant methyl amide derivative (CDDO-MA) was recently shown to afford neuroprotection in vivo against MPTP and 6-OHDA-induced nigral degeneration in mice and rats (Yang et al., 2009).”
BackgroundThe cytoprotective role of the Keap1–Nrf2 pathway
Baird, L., & Dinkova-Kostova, A. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0674-5 · Cited by 1,027
The emerging role of Nrf2 in mitochondrial function
Dinkova-Kostova, A. T., & Abramov, A. Y. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.036 · Cited by 983
“In addition, Nrf2-KO primary neuronal cultures and mice are more sensitive to the toxicity of the complex II inhibitors 3-nitropropionic acid and malonate, whereas intrastriatal transplantation of Nrf2-overexpressing astrocytes is protective [48,49].”
BackgroundTebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837
Mitochondrial Dysfunction in Neurodegenerative Diseases
Johri, A., & Beal, M. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192138 · Cited by 806
Self-citationStress-activated cap’n’collar transcription factors in aging and human disease
Sykiotis, G. P., & Bohmann, D. (2010) · Science Signaling · doi:10.1126/scisignal.3112re3 · Cited by 776
Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Scannevin, R. H., Chollate, S., Jung, M.-Y., Shackett, M., Patel, H., Bista, P., Zeng, W., Ryan, S., Yamamoto, M., Lukashev, M., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190132 · Cited by 461
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
Self-citationLiby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
Self-citationNeuroprotective strategies involving ROS in Alzheimer disease
Dumont, M., & Beal, M. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.026 · Cited by 402
“Similar improvements in behavior and reduced oxidative damage were also found in mouse models of Huntington’s disease [183] and of Parkinson’s disease [184], providing hope for future clinical trials.”
BackgroundSelf-citationNRF2-regulation in brain health and disease: Implication of cerebral inflammation
Sandberg, M., Patil, J., D'Angelo, B., Weber, S. G., & Mallard, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.004 · Cited by 390
The Role of Oxidative Stress in Parkinson’s Disease
Chang, K.-H., & Chen, C.-M. (2020) · Antioxidants · doi:10.3390/antiox9070597 · Cited by 341
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases
Kumar, H., Kim, I.-S., More, S. V., Kim, B.-W., & Choi, D.-K. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70065h · Cited by 333
Nrf2—a therapeutic target for the treatment of neurodegenerative diseases
Johnson, D. A., & Johnson, J. A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.147 · Cited by 321
Sporn, M. B., Liby, K. T., Yore, M. M., Fu, L., Lopchuk, J. M., & Gribble, G. W. (2011) · Journal of Natural Products · doi:10.1021/np100826q · Cited by 312
Self-citationNRF2 as a Therapeutic Target in Neurodegenerative Diseases
Brandes, M. S., & Gray, N. E. (2020) · ASN Neuro · doi:10.1177/1759091419899782 · Cited by 297
“…also induced the expression of antioxidant enzymes and protected against dopaminergic neuronal loss in MPTPtreated mice (Jazwa et al., 2011) as did a NRF2activating synthetic triterpenoid that also reduced ROS levels and upregulated genes involved in mitochondrial biogenesis (Yang et al., 2009).”
BackgroundOxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases
Gan, L., & Johnson, J. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.011 · Cited by 288
“Our lab and others have shown that activation of the Nrf2-ARE pathway can protect against toxicity from mHtt [79,81,123].”
BackgroundMitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 264
Woo, S. Y., Kim, J. H., Moon, M. K., Han, S.-H., Yeon, S. K., Choi, J. W., Jang, B. K., Song, H. J., Kang, Y. G., Kim, J. W., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401788m · Cited by 263
Gibson, G. E., Starkov, A., Blass, J. P., Ratan, R. R., & Beal, M. F. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.010 · Cited by 256
Self-citationSaha, S., Buttari, B., Profumo, E., Tucci, P., & Saso, L. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.787258 · Cited by 185
Tufekci, K. U., Civi Bayin, E., Genc, S., & Genc, K. (2011) · Parkinson's Disease · doi:10.4061/2011/314082 · Cited by 182
“CDDO-MA showed significant protection against both models and tert-butylhydroxyperoxide-induced ROS degeneration [120].”
BackgroundAre Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?
Liddell, J. (2017) · Antioxidants · doi:10.3390/antiox6030065 · Cited by 168
“Dimethyl fumarate MPTP Mouse Yes [13] MPTP Mouse No [66] 6OHDA Mouse No [68] α-synuclein Mouse Yes [67] CDDO–MA MPTP Mouse No [70] CDDO–EA MPTP Mouse Yes [69] CDDO–TFEA MPTP Mouse Yes [69] 3H-1,2-dithiole-3-thione MPTP Mouse Yes [72] Sulforaphane MPTP Mouse Yes [60] 6OHDA Mouse No [61] Rotenone Mouse No [62] α-synucle…”
BackgroundSynthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids
Borella, R., Forti, L., Gibellini, L., De Gaetano, A., De Biasi, S., Nasi, M., Cossarizza, A., & Pinti, M. (2019) · Molecules · doi:10.3390/molecules24224097 · Cited by 98
CNS Peroxiredoxins and Their Regulation in Health and Disease
Bell, K. F. S., & Hardingham, G. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3567 · Cited by 71
Metadata
- Authors
- Yang, L., Calingasan, N. Y., Thomas, B., Chaturvedi, R. K., Kiaei, M., Wille, E. J., Liby, K. T., Williams, C., Royce, D., Risingsong, R., Musiek, E. S., Morrow, J. D., Sporn, M., & Beal, M. F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-06-01
- Volume
- 4
- Issue
- 6
- Pages
- e5757
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2028277827
- Cited by
- 172
- References
- 17
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.